News Sanofi

Stocks

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 11:55:00 2026-06-16 am EDT			5-day change	1st Jan Change
75.66 ^EUR	+0.16%		-1.79%	-8.53%

Jun. 15	European Equities Traded in the US as American Depositary Receipts Surge in Monday Trading	MT
Jun. 15	Global drugmakers invest billions to boost US presence	RE

All News

Mentions Relevance

Jun. 15	Sanofi Says US FDA Approved Tzield for Recently Diagnosed Stage 3 Type 1 Diabetes in Children	MT
Jun. 15	SANOFI : Gets a Buy rating from Deutsche Bank	ZD
Jun. 15	Sanofi Secures Accelerated Approval in Diabetes
Jun. 14	Sanofi Wins US Approval for Disease-modifying Therapy for Diabetes in Children	MT
Jun. 13	Sanofi - Shareholder/Analyst Call
Jun. 12	Sanofi Receives Accelerated Approval for Tzield as First Disease-Modifying Therapy for Stage 3 Type 1 Diabetes	CI
Jun. 12	FDA approves expanded use of Sanofi's type 1 diabetes drug	RE
Jun. 12	Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes	GL
Jun. 12	FDA approves Sanofi's drug for stage 3 type 1 diabetes in children	RE
Jun. 12	Sanofi's Tzield Receives FDA Approval for Diabetes Treatment	DJ
Jun. 10	CIC Corp. & Institutional Banking Trims Sanofi PT, Keeps Buy Rating	MT
Jun. 10	Sanofi Provides Update On Mobilize Phase 3 Study Of Riliprubart In Chronic Inflammatory Demyelinating Polyneuropathy	CI
Jun. 10	Sanofi Terminates Late-stage Trial for Rare Neurological Disorder Treatment; 2026 Guidance Maintained	MT
Jun. 10	Sanofi Stops Late-Stage Trial of Autoimmune Disease Therapy After Interim Review	MT
Jun. 10	Sanofi ends Phase 3 riliprubart trial after weak interim results	RE
Jun. 10	Sanofi to Stop Late-Stage Study of Immune-Disorder Drug	DJ
Jun. 10	Sanofi halts Phase 3 study in CIDP
Jun. 10	Sanofi to Discontinue Late-stage Trial of Riliprubart in Rare Neurological Disorder	MT
Jun. 10	Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy	GL
Jun. 09	SANOFI : Deutsche Bank remains its Buy rating	ZD
Jun. 08	Sanofi Receives European Commission Approval For Sarclisa Subcutaneous As First Anticancer Treatment Administered Via On-Body Injector	CI
Jun. 08	Sanofi's Subcutaneous Sarclisa Approved in EU Across Multiple Myeloma Indications	MT
Jun. 08	Sanofi Wins EU Approval for Subcutaneous Sarclisa in Multiple Myeloma	MT
Jun. 08	Brussels greenlights subcutaneous administration for Sanofi's Sarclisa
Jun. 08	Sanofi’s Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injector	GL